| NCT05985187 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | HER2-positive Breast Cancer | 2020-10-20 | PHASE3 |
| NCT05738993 | Biocad | Breast Cancer | 2022-08-08 | PHASE1 |
| NCT05802225 | Biocad | Breast Cancer | 2023-01-30 | PHASE3 |
| NCT03058939 | University of Chicago | Breast Cancer|Breast Cancer Stage II|Breast Cancer Stage III | 2018-11 | PHASE2 |
| NCT05323981 | BioRay Pharmaceutical Co., Ltd. | Similarity of Pharmacokinetics and Safety | 2022-04-11 | PHASE1 |
| NCT04820439 | The Affiliated Hospital of Qingdao University | Healthy Volunteers | 2020-10-13 | PHASE1 |
| NCT06038539 | Biocon Biologics UK Ltd | HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients | 2025-01-06 | PHASE3 |
| NCT06884254 | EirGenix, Inc. | Early Breast Cancer | 2025-05 | PHASE3 |
| NCT03161353 | MedSIR | Breast Cancer | 2017-06-26 | PHASE2 |
| NCT03674112 | Hoffmann-La Roche | HER2-Positive Early Breast Cancer | 2018-12-19 | PHASE2 |
| NCT05238831 | OHSU Knight Cancer Institute|Genentech, Inc.|Oregon Health and Science University | Advanced Breast Carcinoma|Advanced Malignant Solid Neoplasm|Advanced Ovarian Carcinoma|Advanced Pancreatic Carcinoma|Advanced Prostate Carcinoma|Advanced Sarcoma|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Recurrent Adult Soft Tissue Sarcoma|Recurrent Breast Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Prostate Carcinoma|Stage II Pancreatic Cancer AJCC v8|Stage III Ovarian Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8 | 2023-01-30 | EARLY_PHASE1 |
| NCT01774786 | Hoffmann-La Roche | Gastric Cancer | 2013-06-10 | PHASE3 |
| NCT07093931 | Shandong Cancer Hospital and Institute|Cancer Hospital Chinese Academy of Medical Science | Breast Cancer | 2025-08-01 | PHASE4 |
| NCT06445400 | Sichuan Baili Pharmaceutical Co., Ltd.|Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | HER2-positive Breast Cancer | 2024-06-19 | PHASE2 |
| NCT03144947 | Gruppo Oncologico Italiano di Ricerca Clinica|University Hospital of Parma: Department of Biomedical, Biotechnological and Translational Sciences, Pathological Anatomy and Histology Unit|University Hospital of Parma:Laboratory of Viral Immunopathology, Unit of Infectious Diseases and Hepatology|University Hospital of Parma:Statistica medica ed epidemiologia clinica-UO Ricerca e Innovazione|Clirest s.r.l.|Mipharm SpA|Arithmos srl|Temas srl | Cancer, Breast | 2016-11-29 | PHASE2 |
| NCT05474690 | Henan Cancer Hospital | Breast Cancer|HER2-positive Breast Cancer | 2022-05-11 | PHASE3 |
| NCT04629846 | Qilu Pharmaceutical Co., Ltd. | Breast Cancer | 2020-11-23 | PHASE3 |
| NCT06178159 | RemeGen Co., Ltd. | Breast Cancer | 2023-11-28 | PHASE2 |
| NCT05319873 | Jonsson Comprehensive Cancer Center|Seagen Inc.|Novartis | Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Invasive Breast Carcinoma|Locally Advanced HER2-Positive Breast Carcinoma|Metastatic HER2-Positive Breast Carcinoma|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8 | 2022-04-07 | PHASE1|PHASE2 |
| NCT03365882 | SWOG Cancer Research Network|National Cancer Institute (NCI) | Colon Adenocarcinoma|ERBB2 Gene Amplification|Rectal Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage III Colon Cancer AJCC v7|Stage III Rectal Cancer AJCC v7|Stage IIIA Colon Cancer AJCC v7|Stage IIIA Rectal Cancer AJCC v7|Stage IIIB Colon Cancer AJCC v7|Stage IIIB Rectal Cancer AJCC v7|Stage IIIC Colon Cancer AJCC v7|Stage IIIC Rectal Cancer AJCC v7|Stage IV Colon Cancer AJCC v7|Stage IV Rectal Cancer AJCC v7|Stage IVA Colon Cancer AJCC v7|Stage IVA Rectal Cancer AJCC v7|Stage IVB Colon Cancer AJCC v7|Stage IVB Rectal Cancer AJCC v7 | 2017-11-27 | PHASE2 |
| NCT04993014 | AC Camargo Cancer Center | Breast Neoplasms|HER2-positive Breast Cancer|Circulating Tumor Cell | 2021-03-01 | PHASE2 |
| NCT03297606 | Canadian Cancer Trials Group|AstraZeneca|Bristol-Myers Squibb|Hoffmann-La Roche|Pfizer|Seagen Inc. | Lymphoma, Non-Hodgkin|Multiple Myeloma|Advanced Solid Tumors | 2018-03-23 | PHASE2 |
| NCT05525858 | Seoul National University Bundang Hospital|Korean Cancer Study Group|Roche Pharma AG | Solid Tumor|Advanced Solid Tumor|Metastatic Cancer | 2022-09-28 | |
| NCT05415215 | Hoffmann-La Roche | Early Breast Cancer|Locally Advanced Breast Cancer|Inflammatory Breast Cancer | 2022-07-05 | PHASE3 |
| NCT02598427 | Kimberly Blackwell | HER2 Positive Untreated Metastatic Breast Cancer|Asymptomatic or Low Symptomatic Brain Metastasis in Breast Cancer | 2017-05-01 | PHASE1 |
| NCT00781612 | Genentech, Inc.|Hoffmann-La Roche | Neoplasm Metastasis | 2008-10-16 | PHASE2 |
| NCT06348134 | University of Chicago | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast|HER2-positive Breast Cancer|Breast Cancer | 2025-03-18 | PHASE2 |
| NCT01108458 | George Albert Fisher|Genentech, Inc. | Pancreatic Cancer | 2010-07 | PHASE2 |
| NCT02480010 | Hoffmann-La Roche | Prostate Cancer | 2003-09 | PHASE2 |
| NCT02625441 | Helsinki University Central Hospital | Breast Cancer | 2015-12 | PHASE3 |
| NCT07528898 | Hebei Medical University Fourth Hospital|Jiangsu Hengrui Pharmaceutical Co., Ltd. | Breast Cancer | 2026-05 | PHASE2 |
| NCT07047755 | Henan Cancer Hospital | Breast Cancer | 2025-07-01 | PHASE2 |
| NCT01120184 | Hoffmann-La Roche|Genentech, Inc. | Breast Cancer | 2010-07-31 | PHASE3 |
| NCT00096941 | Genentech, Inc. | Solid Cancers | 2005-05 | PHASE2 |
| NCT06162559 | The Netherlands Cancer Institute|Seagen Inc. | Breast Cancer | 2023-12-18 | PHASE1 |
| NCT05912062 | Institut Català d´Oncologia|Instituto de Salud Carlos III|Fundación Sociedad Espa?ola de Oncologia Médica|Institut d´Investigacions Biomèdiques August Pi i Sunyer|Reveal Genomics (Registered trademark) | HER2-positive Breast Cancer|Neoplasms|Breast Cancer | 2021-03-22 | |
| NCT03264547 | Japan Breast Cancer Research Group|Eisai Co., Ltd. | Breast Cancer | 2017-08-28 | PHASE3 |
| NCT00063154 | Genentech, Inc. | Non-small Cell Lung Cancer | 2003-07 | PHASE2 |
| NCT07246317 | Tianjin Medical University Cancer Institute and Hospital | Breast Cancer | 2025-12-15 | PHASE2 |
| NCT04717531 | The First Affiliated Hospital with Nanjing Medical University | Breast Cancer | 2021-06-03 | PHASE2 |
| NCT04341181 | Ulrik Lassen|Roche Pharma AG|Pfizer|GlaxoSmithKline | Cancer|Tumors|Neoplasms|Neoplasia | 2020-08-24 | PHASE2 |
| NCT02139358 | H. Lee Moffitt Cancer Center and Research Institute|Genentech, Inc. | Breast Cancer | 2014-09-05 | PHASE1|PHASE2 |
| NCT05720026 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | HER2-positive Breast Cancer | 2023-01-09 | PHASE3 |
| NCT03199885 | National Cancer Institute (NCI)|NRG Oncology | Metastatic Breast Adenocarcinoma|Metastatic HER2-Positive Breast Carcinoma|Recurrent Breast Adenocarcinoma|Recurrent HER2-Positive Breast Carcinoma|Stage III Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7|Unresectable Breast Carcinoma|Unresectable HER2-Positive Breast Carcinoma | 2019-04-05 | PHASE3 |
| NCT04208178 | Novartis Pharmaceuticals | Advanced HER2&addition;Breast Cancer | 2020-07-16 | PHASE3 |
| NCT07565324 | National Taiwan University Hospital|TTY Biopharm | HER-2 Positive Breast Cancer | 2026-04-30 | PHASE2 |
| NCT01966471 | Hoffmann-La Roche | Breast Cancer | 2014-01-31 | PHASE3 |
| NCT03112590 | H. Lee Moffitt Cancer Center and Research Institute|Horizon Pharma Ireland, Ltd., Dublin Ireland | Breast Cancer|Breast Cancer, Male|Breast Cancer Female|HER2-positive Breast Cancer | 2017-06-23 | PHASE1|PHASE2 |
| NCT02379585 | Western Regional Medical Center | HER2-positive Breast Cancer | 2013-01 | PHASE1|PHASE2 |
| NCT02514681 | Japan Breast Cancer Research Group|Chugai Pharmaceutical | HER2-positive Locally Advanced or Metastatic Breast Cancer | 2015-08-01 | PHASE3 |
| NCT02789657 | Brown University|Women and Infants Hospital of Rhode Island|Rhode Island Hospital|The Miriam Hospital | Breast Cancer | 2016-11-21 | PHASE2 |
| NCT01904903 | Medstar Health Research Institute|Genentech, Inc. | HER2 Positive Breast Cancer|Left Ventricular Function Systolic Dysfunction | 2013-10 | PHASE2 |
| NCT07421141 | National Medical Research Radiological Centre of the Ministry of Health of Russia | Breast Cancer|HER2-positive Breast Cancer|Early Breast Cancer | 2023-09-01 | PHASE2 |
| NCT02624973 | Haukeland University Hospital|Helse Vest|Pfizer|AstraZeneca | Breast Cancer | 2016-04-15 | PHASE2 |
| NCT02689921 | Midwestern Regional Medical Center | Breast Neoplasms | 2016-04 | PHASE2 |
| NCT01855828 | Yale University|Genentech, Inc. | Her2-Positive Breast Cancer | 2013-09 | PHASE2 |
| NCT07545044 | Shanghai JMT-Bio Inc. | HER2-positive Recurrent or Metastatic Breast Cancer | 2026-05-30 | PHASE2 |
| NCT01912963 | Dana-Farber Cancer Institute|Eisai Inc.|Genentech, Inc. | HER2-positive Breast Cancer|Metastatic Breast Cancer | 2013-09 | PHASE2 |
| NCT04680442 | Population Health Research Institute | Breast Cancer|Heart Failure | 2021-07-01 | PHASE2 |
| NCT03726879 | Hoffmann-La Roche|Chugai Pharmaceutical | Breast Cancer | 2019-01-11 | PHASE3 |
| NCT06441890 | University of Illinois at Chicago | Breast Cancer|HER2-positive Breast Cancer | 2024-12-05 | PHASE2 |
| NCT06278870 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | HER2-positive Metastatic Breast Cancer|First-line Treatment | 2023-09-06 | PHASE3 |
| NCT03742986 | NYU Langone Health | Breast Cancer | 2019-05-02 | PHASE2 |
| NCT07518173 | Sichuan Baili Pharmaceutical Co., Ltd.|Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | HER2-positive Breast Cancer | 2026-04 | PHASE3 |
| NCT02390427 | Otto Metzger, MD|Genentech, Inc. | Metastatic Breast Cancer|Recurrent Breast Cancer | 2015-04-20 | PHASE1 |
| NCT01276041 | Memorial Sloan Kettering Cancer Center|Genentech, Inc.|University of Pennsylvania | Breast Cancer | 2011-01-05 | PHASE2 |
| NCT05385705 | Vall d´Hebron Institute of Oncology|Clinica Universidad de Navarra, Universidad de Navarra|Puerta de Hierro University Hospital|Hospital del Mar|Banc de Sang i Teixits | Breast Neoplasms | 2022-05-11 | PHASE1 |
| NCT07245797 | Zhimin Shao | Breast Cancer | 2025-12-15 | PHASE2 |
| NCT06876714 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) | Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Early Stage Breast Carcinoma | 2025-09-17 | PHASE3 |
| NCT01796197 | Dana-Farber Cancer Institute | Breast Cancer | 2013-08 | PHASE2 |
| NCT02402712 | Hoffmann-La Roche | Breast Cancer | 2015-05-06 | PHASE3 |
| NCT04108858 | National Cancer Institute (NCI) | Anatomic Stage IV Breast Cancer AJCC v8|HER2-Positive Breast Carcinoma|Metastatic Breast Carcinoma | 2021-05-20 | PHASE1|PHASE2 |
| NCT04266249 | ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI) | Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Invasive Breast Carcinoma|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8 | 2020-03-13 | PHASE2 |
| NCT04398914 | Shanghai Jiao Tong University School of Medicine|Jiangsu HengRui Medicine Co., Ltd. | Breast Cancer Invasive | 2020-05-30 | PHASE2 |
| NCT03125928 | Fox Chase Cancer Center|Genentech, Inc. | HER2-positive Breast Cancer | 2017-06-13 | PHASE2 |
| NCT01491737 | Hoffmann-La Roche | Breast Cancer | 2012-02-17 | PHASE2 |
| NCT05582499 | Fudan University | Breast Neoplasm|Breast Cancer|Breast Tumors|Triple-Negative Breast Cancer (TNBC)|HER2-positive Breast Cancer|HER2-negative Breast Cancer|Hormone Receptor Positive Tumor|Hormone Receptor Negative Tumor|Early-stage Breast Cancer|Locally Advanced Breast Cancer | 2022-11-01 | PHASE2 |
| NCT03101748 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | Breast Inflammatory Carcinoma|Locally Advanced Breast Carcinoma|Metastatic Breast Carcinoma|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7 | 2018-02-19 | PHASE1|PHASE2 |
| NCT05325632 | H. Lee Moffitt Cancer Center and Research Institute|ImmunoRestoration | HER2-positive Breast Cancer | 2021-10-28 | PHASE2 |
| NCT07187752 | Shandong Cancer Hospital and Institute | Breast Cancer | 2025-09-30 | NA |
| NCT07294534 | Shanghai Henlius Biotech | HER2 &addition; Breast Cancer | 2026-01-27 | PHASE2|PHASE3 |
| NCT02019277 | Hoffmann-La Roche | Breast Cancer | 2013-12-05 | PHASE3 |
| NCT01817452 | West German Study Group|Roche Pharma AG | Breast Cancer | 2014-03 | PHASE2 |
| NCT02205047 | European Organisation for Research and Treatment of Cancer - EORTC | Malignant Neoplasm of Stomach|Malignant Neoplasm of Cardio-esophageal Junction of Stomach|Epidermal Growth Factor Receptor (EGFR) Protein Overexpression | 2015-07-15 | PHASE2 |
| NCT06136897 | National Cancer Institute (NCI) | Malignant Solid Neoplasm | 2017-03-23 | PHASE2 |
| NCT06145308 | Peking Union Medical College|Peking University Hospital of Stomatology | Salivary Gland Carcinoma|Precision Therapy | 2023-08-15 | PHASE2 |
| NCT04329065 | University of Washington|United States Department of Defense | Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8 | 2022-04-20 | PHASE2 |
| NCT03595592 | Fondazione Michelangelo|Hoffmann-La Roche | Invasive Breast Cancer | 2018-09-07 | PHASE3 |
| NCT02896855 | Hoffmann-La Roche | Breast Cancer | 2016-09-13 | PHASE3 |
| NCT00934856 | Hoffmann-La Roche | Breast Cancer | 2009-07 | PHASE1|PHASE2 |
| NCT07053085 | Memorial Sloan Kettering Cancer Center|Gateway for Cancer Research | Metastatic Breast Cancer|HER2-positive Breast Cancer | 2025-09-17 | PHASE2 |
| NCT07377643 | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | HER2-positive Breast Cancer | 2026-02-10 | PHASE3 |
| NCT07140393 | Jiangsu HengRui Medicine Co., Ltd. | Solid Tumor | 2025-10 | PHASE1|PHASE2 |
| NCT03498521 | Hoffmann-La Roche|Foundation Medicine | Cancer of Unknown Primary Site | 2018-07-10 | PHASE2 |
| NCT02536339 | Genentech, Inc. | Metastatic Breast Cancer | 2015-12-16 | PHASE2 |
| NCT02445586 | Hoffmann-La Roche | Breast Cancer | 2015-08-17 | PHASE4 |
| NCT02004093 | Hoffmann-La Roche | Ovarian Cancer | 2005-12 | PHASE2 |
| NCT03747120 | University of Texas Southwestern Medical Center|Merck Sharp & Dohme LLC|Breast Cancer Research Foundation | HER2-positive Breast Cancer|Breast Cancer | 2019-01-25 | PHASE2 |
| NCT05786716 | Cancer Research UK|University of Manchester|University of Birmingham|Royal Marsden NHS Foundation Trust|Hoffmann-La Roche | Haematological Malignancy|Colorectal Neoplasms|Urinary Bladder Neoplasm|Gallbladder Neoplasms|Salivary Gland Neoplasm|Lung Neoplasm|Pancreatic Neoplasm|Ovarian Neoplasms|Prostatic Neoplasm|Skin Neoplasm|Solid Tumour | 2023-03-07 | PHASE2|PHASE3 |
| NCT06891833 | Sichuan Baili Pharmaceutical Co., Ltd.|Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | HER2-positive Breast Cancer | 2025-06-05 | PHASE2|PHASE3 |
| NCT04425018 | Dana-Farber Cancer Institute|MacroGenics|Translational Breast Cancer Research Consortium | Breast Cancer|Stage II Breast Cancer|Stage III Breast Cancer|HER2-positive Breast Cancer | 2020-07-13 | PHASE2 |
| NCT01684878 | Hoffmann-La Roche | Ovarian Cancer | 2012-10-22 | PHASE3 |
| NCT00058539 | Genentech, Inc. | Prostate Cancer | 2003-04 | PHASE2 |
| NCT07102381 | Jazz Pharmaceuticals|Jazz Pharmaceuticals Ireland Limited | HER2-positive Breast Cancer|Breast Cancer | 2025-09-24 | PHASE2 |
| NCT04588545 | H. Lee Moffitt Cancer Center and Research Institute|Genentech, Inc. | HER2-positive Breast Cancer|Leptomeningeal Metastasis|Leptomeningeal Disease | 2020-12-10 | PHASE1|PHASE2 |
| NCT02568839 | Thomas Hatschek | Early-Stage Breast Carcinoma|HER-2 Positive Breast Cancer | 2014-11 | PHASE2|PHASE3 |
| NCT05420454 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Breast Cancer | 2022-07-10 | PHASE4 |
| NCT02827877 | City of Hope Medical Center|National Cancer Institute (NCI) | HER2 Positive Breast Carcinoma|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer | 2016-07-15 | PHASE2 |
| NCT02091141 | Genentech, Inc. | Neoplasms|Solid Tumors|Biliary Cancer|Salivary Cancer|Bladder Cancer | 2014-04-14 | PHASE2 |
| NCT02132949 | Hoffmann-La Roche | Breast Cancer | 2014-07-14 | PHASE2 |
| NCT04197687 | Academic and Community Cancer Research United|National Cancer Institute (NCI) | Breast Adenocarcinoma|Stage II Breast Cancer AJCC v6 and v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7 | 2020-02-20 | PHASE2 |
| NCT07116824 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | HER2-positive Breast Cancer | 2025-09-15 | PHASE2 |
| NCT02073487 | The Methodist Hospital Research Institute|Celgene Corporation|Novartis | Breast Cancer | 2014-02 | PHASE2 |
| NCT05760612 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Early-stage Breast Cancer|HER2-positive Breast Cancer|Adjuvant Treatment After Trastuzumab|RCB Classification 1-2|Neratini | 2023-03-14 | PHASE3 |
| NCT07335081 | Shanghai Jiao Tong University School of Medicine | Breast Cancer | 2024-02-01 | PHASE2 |
| NCT03006172 | Genentech, Inc. | Breast Cancer|Solid Tumor | 2016-12-13 | PHASE1 |
| NCT01597414 | European Organisation for Research and Treatment of Cancer - EORTC|Hoffmann-La Roche | Elderly Metastatic Breast Cancer Population | 2013-06 | PHASE2 |
| NCT07371585 | SOLTI Breast Cancer Research Group|Westdeutsche Studiengruppe GmbH (WSG)|UNICANCER | Breast Cancer Stage IV | 2026-02-18 | PHASE2 |
| NCT05900206 | Karolinska University Hospital | Breast Cancer | 2023-10-26 | PHASE2 |
| NCT01730833 | City of Hope Medical Center|National Cancer Institute (NCI) | HER2-positive Breast Cancer|Recurrent Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Breast Adenocarcinoma|Inflammatory Breast Carcinoma | 2013-07-17 | PHASE2 |
| NCT05749016 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Locally Advanced Breast Cancer|Chemotherapy Effect | 2021-11-01 | PHASE2 |
| NCT00976989 | Hoffmann-La Roche | Breast Cancer | 2009-11 | PHASE2 |
| NCT02125344 | GBG Forschungs GmbH|Amgen|Roche Pharma AG|Teva Pharmaceuticals USA|Vifor Pharma | Tubular Breast Cancer Stage II|Tubular Breast Cancer Stage III|Mucinous Breast Cancer Stage II|Breast Cancer Female NOS|Invasive Ductal Breast Cancer|HER2 Positive Breast Cancer|Inflammatory Breast Cancer | 2014-12 | PHASE3 |
| NCT02060253 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Synta Pharmaceuticals Corp.|New York University Cancer Institute | HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer | 2014-04 | PHASE1 |
| NCT05891561 | Shanghai Jiao Tong University School of Medicine | Breast Cancer | 2023-11-01 | PHASE2 |
| NCT07294508 | Shanghai Henlius Biotech | HER2 &addition; Breast Cancer | 2026-02-27 | PHASE2|PHASE3 |
| NCT02003209 | National Cancer Institute (NCI)|NRG Oncology | HER2-Positive Breast Carcinoma|Hormone Receptor-Positive Breast Carcinoma|Stage IB Breast Cancer AJCC v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7 | 2014-02-18 | PHASE3 |
| NCT06771622 | FBD Biologics Limited | Solid Cancer | 2025-03-13 | PHASE1|PHASE2 |
| NCT02320435 | Hoffmann-La Roche | Solid Tumors | 2015-02-02 | PHASE3 |
| NCT04538742 | AstraZeneca|Daiichi Sankyo Company, Limited | Metastatic Breast Cancer | 2020-12-28 | PHASE1|PHASE2 |
| NCT03845270 | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer Metastatic|Non Small Cell Lung Cancer Stage III|HER2 Gene Mutation | 2019-05-17 | PHASE2 |
| NCT01042379 | QuantumLeap Healthcare Collaborative | Breast Neoplasms|Breast Cancer|Breast Tumors|Angiosarcoma|TNBC - Triple-Negative Breast Cancer|HER2-positive Breast Cancer|HER2-negative Breast Cancer|Hormone Receptor Positive Tumor|Hormone Receptor Negative Tumor|Early-stage Breast Cancer|Locally Advanced Breast Cancer | 2010-03-01 | PHASE2 |
| NCT02229149 | US Oncology Research|Genentech, Inc. | Breast Neoplasms|Malignant Tumor of the Breast | 2014-12 | PHASE2 |
| NCT05838066 | Shanghai JMT-Bio Inc. | First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer | 2023-07-23 | PHASE3 |
| NCT01959490 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) | Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer | 2013-09-24 | PHASE2 |
| NCT02909751 | Vejle Hospital | Breast Cancer | 2016-09-14 | PHASE2 |
| NCT07129018 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Biliary Tract Cancer (BTC)|First-line Therapy | 2025-11 | PHASE2 |
| NCT00947167 | Pamela L. Kunz|Genentech, Inc. | Neuroendocrine Tumors|Carcinoid Tumors|Adrenal Gland Tumors|Neuroblastoma|Pancreatic Neuroendocrine Tumors|Multiple Endocrine Neoplasia | 2009-03 | PHASE2 |
| NCT06510465 | RenJi Hospital | Breast Cancer | 2024-08-01 | PHASE2 |
| NCT04760431 | Second Affiliated Hospital, School of Medicine, Zhejiang University|Peking University International Hospital|Sun Yat-sen University|Zhejiang University | HER2-positive Breast Cancer|Brain Metastases | 2021-10-01 | PHASE2 |
| NCT05983094 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Chinese Academy of Medical Sciences|Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center|First Hospital of China Medical University | Breast Cancer|Neoadjuvant Therapy | 2023-09-01 | PHASE2 |
| NCT04024462 | Hoffmann-La Roche | HER2-positive Early Breast Cancer | 2020-02-05 | PHASE3 |
| NCT00943670 | Genentech, Inc. | Metastatic Breast Cancer | 2009-07 | PHASE2 |
| NCT05020860 | Baylor Breast Care Center | Breast Cancer|Breast Neoplasm|Breast Cancer Female|Breast Cancer Invasive|Breast Cancer Stage II|Breast Cancer Stage III|Triple Negative Breast Cancer|Hormone Receptor-positive Breast Cancer|HER2-positive Breast Cancer|Triple Negative Breast Neoplasms|Estrogen Receptor-positive Breast Cancer | 2023-04-18 | PHASE2 |
| NCT02465060 | National Cancer Institute (NCI) | Advanced Lymphoma|Advanced Malignant Solid Neoplasm|Bladder Carcinoma|Breast Carcinoma|Cervical Carcinoma|Colon Carcinoma|Colorectal Carcinoma|Endometrial Carcinoma|Esophageal Carcinoma|Exocrine Pancreas Carcinoma|Gastric Carcinoma|Glioma|Head and Neck Carcinoma|Hematopoietic and Lymphoid Cell Neoplasm|Kidney Carcinoma|Liver Carcinoma|Lung Carcinoma|Lymphoma|Malignant Uterine Corpus Neoplasm|Malignant Uterine Neoplasm|Melanoma|Multiple Myeloma|Ovarian Carcinoma|Prostate Carcinoma|Rectal Carcinoma|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Cervical Carcinoma|Recurrent Colon Carcinoma|Recurrent Colorectal Carcinoma|Recurrent Esophageal Carcinoma|Recurrent Gastric Carcinoma|Recurrent Glioma|Recurrent Head and Neck Carcinoma|Recurrent Liver Carcinoma|Recurrent Lung Carcinoma|Recurrent Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Malignant Uterine Corpus Neoplasm|Recurrent Melanoma|Recurrent Multiple Myeloma|Recurrent Ovarian Carcinoma|Recurrent Pancreatic Carcinoma|Recurrent Prostate Carcinoma|Recurrent Rectal Carcinoma|Recurrent Skin Carcinoma|Recurrent Thyroid Gland Carcinoma|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Multiple Myeloma|Skin Carcinoma|Thyroid Gland Carcinoma | 2015-08-17 | PHASE2 |
| NCT01026142 | Hoffmann-La Roche | Breast Cancer | 2010-01-26 | PHASE3 |
| NCT05426486 | Caigang Liu | HER2-positive Breast Cancer | 2022-05-23 | PHASE2|PHASE3 |
| NCT06686394 | Merck Sharp & Dohme LLC|Daiichi Sankyo | Breast Neoplasms|Breast Cancer | 2025-02-26 | PHASE1|PHASE2 |
| NCT03811418 | iOMEDICO AG|Arbeitsgemeinschaft fur Internistische Onkologie|Amgen | Advanced Breast Cancer|HER2-positive Breast Cancer | 2019-01 | PHASE3 |
| NCT07441460 | Shanghai JMT-Bio Inc. | Resectable HER2-positive Breast Cancer | 2026-03-06 | PHASE3 |
| NCT04411550 | Shanghai Henlius Biotech | Healthy Male Volunteers | 2020-07-01 | PHASE1 |
| NCT05825781 | Mabscale, LLC | Healthy Men | 2023-07-20 | PHASE1 |
| NCT06907082 | Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia | Breast Cancer | 2020-12-28 | NA |
| NCT07196774 | Jiangsu HengRui Medicine Co., Ltd. | Early-stage or Locally Advanced HER2-positive Breast Cancer | 2025-10-23 | PHASE3 |
| NCT02682693 | GBG Forschungs GmbH|Amgen|Celgene Corporation | Breast Cancer Female NOS|Tubular Breast Cancer Stage II|Mucinous Breast Cancer Stage II|Invasive Ductal Breast Cancer|HER2 Positive Breast Cancer|Inflammatory Breast Cancer|Tubular Breast Cancer Stage III | 2017-02-13 | PHASE2 |
| NCT06057610 | Jiangsu HengRui Medicine Co., Ltd. | HER2-PositiveRecurrent or Metastatic Breast Cancer | 2023-10-16 | PHASE3 |
| NCT05722886 | Cancer Research UK|University of Manchester|University of Birmingham|Royal Marsden NHS Foundation Trust|Hoffmann-La Roche|Novartis Pharmaceuticals | Haematological Malignancy|Solid Tumour | 2023-03-01 | PHASE2|PHASE3 |
| NCT03820141 | The Methodist Hospital Research Institute|AstraZeneca | Breast Cancer | 2020-06-30 | PHASE2 |
| NCT00551421 | National Cancer Institute (NCI) | Adenocarcinoma of the Colon|Adenocarcinoma of the Rectum|Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage III Colon Cancer|Stage III Rectal Cancer|Stage IV Colon Cancer|Stage IV Rectal Cancer | 2007-10 | PHASE1|PHASE2 |
| NCT00058552 | Genentech, Inc. | Ovarian Cancer | 2003-05 | PHASE2 |
| NCT05036005 | Institut fuer Frauengesundheit|Samsung Bioepis Co., Ltd. | Breast Cancer|Breast Neoplasms|Breast Cancer Female|HER2-positive Breast Cancer | 2021-07-11 | PHASE4 |
| NCT04632992 | Genentech, Inc. | Advanced Unresectable or Metastatic Solid Malignancy | 2021-01-13 | PHASE2 |
| NCT01565083 | Hoffmann-La Roche | Breast Cancer | 2012-04 | PHASE2 |
| NCT05978648 | wang shusen | Breast Neoplasms | 2023-09-20 | PHASE2 |
| NCT05574881 | Fudan University | Breast Cancer | 2022-09-01 | PHASE1|PHASE2 |
| NCT02436993 | University of California, Irvine | Breast Carcinoma | 2015-04 | PHASE2 |
| NCT05113251 | AstraZeneca|Daiichi Sankyo | Breast Neoplasms|Breast Cancer|HER2-positive Early Breast Cancer | 2021-10-25 | PHASE3 |
| NCT03803553 | Massachusetts General Hospital|Stand Up To Cancer | Metastatic Colon Cancer|Stage III Colon Cancer | 2020-04-16 | PHASE3 |
| NCT04193059 | Fudan University | Breast Cancer | 2019-12-20 | PHASE3 |
| NCT04957212 | Cinnagen | HER2-positive Breast Cancer | 2018-08-11 | PHASE3 |
| NCT04578106 | Fundacio Clinic Barcelona|SOLTI Breast Cancer Research Group|Roche Pharma AG | HER2-positive Breast Cancer|Stage I Breast Cancer | 2020-09-23 | PHASE2 |
| NCT02120911 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Roche Pharma AG | Esophageal Carcinoma | 2014-01 | PHASE1|PHASE2 |
| NCT03135171 | University of Michigan Rogel Cancer Center | Breast Cancer | 2017-07-26 | PHASE1 |
| NCT00833963 | Genentech, Inc. | Breast Cancer|Pregnancy | 2009-01-14 | |
| NCT03894007 | Renske Altena | Early-stage Breast Cancer|HER2-positive Breast Cancer | 2019-05-23 | PHASE2 |
| NCT01572038 | Hoffmann-La Roche | Breast Neoplasms | 2012-06-01 | PHASE3 |
| NCT05275010 | Hoffmann-La Roche | Healthy Male Subjects | 2022-05-30 | PHASE1 |
| NCT06927180 | Henan Cancer Hospital | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | 2025-04-16 | PHASE2 |
| NCT02925234 | The Netherlands Cancer Institute|Amgen|AstraZeneca|Bayer|Bristol-Myers Squibb|Novartis|Roche Pharma AG|Merck Sharp & Dohme LLC|Boehringer Ingelheim|Ipsen|Eisai Inc.|Pfizer|Clovis Oncology - Pharma and|Eli Lilly and Company|Janssen, LP|GlaxoSmithKline|Incyte Corporation|Dutch Cancer Society|Stelvio for Life | Cancer|Tumors|Neoplasm|Neoplasia | 2016-08 | PHASE2 |
| NCT01922921 | University of Washington|National Cancer Institute (NCI)|National Center for Complementary and Integrative Health (NCCIH) | HER2+Neu Positive|Recurrent Breast Carcinoma|Stage IV Breast Cancer | 2014-02-05 | PHASE1|PHASE2 |
| NCT06490536 | IFOM ETS - The AIRC Institute of Molecular Oncology | Colon Cancer Stage II|Colon Cancer Stage III | 2024-10-22 | PHASE3 |
| NCT02345772 | Western Regional Medical Center | HER2-positive Breast Cancer|ER-positive Breast Cancer | 2014-07 | PHASE1|PHASE2 |
| NCT02057133 | Eli Lilly and Company | Breast Neoplasms | 2014-03-10 | PHASE1 |
| NCT07299890 | Anhui Provincial Cancer Hospital | Breast Cancer | 2025-12-20 | PHASE2 |
| NCT05429684 | First Affiliated Hospital Xi´an Jiaotong University | HER2&addition; Breast Cancer | 2021-01-01 | PHASE3 |
| NCT07407920 | M.D. Anderson Cancer Center | Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Early Stage HER2-Positive Breast Carcinoma|Early Stage Triple-Negative Breast Carcinoma | 2025-10-09 | PHASE2 |
| NCT02947685 | Alliance Foundation Trials, LLC.|Pfizer|GBG Forschungs GmbH|Fondazione Michelangelo|PrECOG, LLC.|Breast Cancer Trials, Australia and New Zealand|Syneos Health|SOLTI Breast Cancer Research Group|UNICANCER | HER-2 Positive Breast Cancer|Estrogen Receptor Positive Breast Cancer | 2017-06-21 | PHASE3 |
| NCT02605915 | Hoffmann-La Roche | HER2-Positive Metastatic Breast Cancer|HER2-Negative Metastatic Breast Cancer|Locally Advanced or Early Breast Cancer | 2015-12-31 | PHASE1 |
| NCT05132582 | Seagen, a wholly owned subsidiary of Pfizer | HER2 Positive Breast Cancer | 2022-03-07 | PHASE3 |
| NCT02530424 | Fondazione Michelangelo | Breast Neoplasms | 2015-05 | PHASE2 |
| NCT01674062 | Hoffmann-La Roche | Breast Cancer | 2006-05 | PHASE2 |
| NCT06439693 | Dana-Farber Cancer Institute|Translational Breast Cancer Research Consortium|Johns Hopkins University | Breast Cancer Female|Breast Cancer|Breast Cancer Metastatic|Estrogen Receptor-positive Breast Cancer|HER2-positive Breast Cancer|Stage IV Breast Cancer | 2024-08-08 | PHASE2 |
| NCT02411344 | Istituto Oncologico Veneto IRCCS|Association for Translational Research in Oncology (AS.T.R.O.) | Endocrine Sensitive HER2&addition;+HR&addition; Breast Cancer | 2014-02 | PHASE2 |
| NCT02491892 | Hoffmann-La Roche | Breast Cancer | 2003-02 | PHASE2 |
| NCT04900311 | Tianjin Medical University Cancer Institute and Hospital|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | HER2&addition; Early or Locally Advanced Breast Cancer | 2021-05 | PHASE2 |
| NCT03716180 | Dana-Farber Cancer Institute|Susan G. Komen Breast Cancer Foundation|Breast Cancer Research Foundation|Terri Brodeur Breast Cancer Foundation | Breast Cancer | 2018-11-05 | PHASE1 |
| NCT06747338 | Shanghai JMT-Bio Inc. | Early or Locally Advanced HER2-positive Breast Cancer | 2024-12-16 | PHASE3 |
| NCT03412643 | NSABP Foundation Inc|Celcuity, LLC|Genentech, Inc. | HER2-negative Breast Cancer | 2018-05-14 | PHASE2 |
| NCT07043725 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | HER2-positive Breast Cancer | 2025-09-15 | PHASE3 |
| NCT00875979 | Hoffmann-La Roche|Roche Pharma AG | Metastatic Breast Cancer | 2009-05 | PHASE1|PHASE2 |
| NCT07220135 | University of Kansas Medical Center | Breast Cancer | 2025-11-14 | PHASE2 |
| NCT00567190 | Genentech, Inc.|Hoffmann-La Roche | Metastatic Breast Cancer | 2008-02-12 | PHASE3 |
| NCT05572645 | Fudan University | Breast Cancer | 2022-10-01 | |
| NCT03493854 | Hoffmann-La Roche | Early Breast Cancer | 2018-06-14 | PHASE3 |
| NCT01847001 | Columbia University | Locally Advanced Malignant Neoplasm|Breast Cancer | 2012-10 | PHASE2 |
| NCT01358877 | Hoffmann-La Roche|Genentech, Inc.|Breast International Group | Breast Cancer | 2011-11-08 | PHASE3 |
| NCT00301899 | National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI) | Breast Cancer | 2005-12 | PHASE2 |
| NCT05159193 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|CSPC Ouyi Pharmaceutical Co., Ltd. | Breast Cancer | 2021-12-20 | PHASE3 |
| NCT01850628 | NSABP Foundation Inc|Breast Cancer Research Foundation|Washington University School of Medicine | Breast Cancer | 2013-07 | |
| NCT07416409 | Deraya University | Breast Neoplasms|Oncology|HER2-positive Breast Cancer|Metastatic Breast Cancer | 2023-06-10 | |
| NCT03417544 | Nancy Lin, MD|Genentech, Inc. | HER2-positive Metastatic Breast Cancer|Central Nervous System Metastases | 2018-05-21 | PHASE2 |
| NCT02507375 | Hoffmann-La Roche | Non-Small Cell Lung Cancer | 2006-09 | PHASE1 |
| NCT02738970 | Hoffmann-La Roche | Early Breast Cancer | 2016-06-23 | PHASE1 |
| NCT00951665 | Genentech, Inc. | Metastatic Breast Cancer | 2009-08 | PHASE1|PHASE2 |
| NCT04591431 | Fondazione per la Medicina Personalizzata | Breast Cancer|Gastrointestinal Cancer|Non Small Cell Lung Cancer|Other Cancer | 2020-10-07 | PHASE2 |
| NCT03225937 | Fondazione del Piemonte per l´Oncologia | Metastatic Colorectal Cancer | 2012-08 | PHASE2 |
| NCT04301375 | David Garcia Cinca|Fundacion Clinic per a la Recerca Biomédica | Mammary Cancer | 2020-06-15 | PHASE2 |
| NCT02131064 | Hoffmann-La Roche | Breast Neoplasms | 2014-06-25 | PHASE3 |
| NCT05323955 | Carey Anders, M.D.|Pfizer | Brain Metastases|Human Epidermal Growth Factor 2 Positive Carcinoma of Breast|Advanced Breast Cancer | 2023-03-23 | PHASE2 |
| NCT02693535 | American Society of Clinical Oncology|AstraZeneca|Bayer|Bristol-Myers Squibb|Eli Lilly and Company|Genentech, Inc.|Pfizer|Taiho Oncology, Inc.|Novartis|Merck Institute for Therapeutic Research|Boehringer Ingelheim|Seattle Genetics (now a wholly owned subsidiary of Pfizer) | Lymphoma, Non-Hodgkin|Multiple Myeloma|Advanced Solid Tumors | 2016-03-14 | PHASE2 |
| NCT01121939 | SCRI Development Innovations, LLC|Genentech, Inc. | Neuroendocrine Carcinoma | 2010-05 | PHASE2 |
| NCT06578299 | Fudan University | Breast Cancer Stage IV | 2024-08-30 | PHASE4 |
| NCT04514419 | BioRay Pharmaceutical Co., Ltd. | Breast Cancer | 2020-06-28 | PHASE3 |
| NCT05883852 | Fudan University | HER2 Positive Early Breast Cancer | 2023-06-07 | PHASE3 |
| NCT05638594 | Shengjing Hospital | Breast Cancer | 2022-12-20 | PHASE2 |
| NCT04337658 | Second Affiliated Hospital, School of Medicine, Zhejiang University | HER2-positive Breast Cancer | 2020-07-01 | PHASE3 |
| NCT04675827 | Jules Bordet Institute|Breast International Group|Hoffmann-La Roche|International Drug Development Institute|Institut Curie | HER2-positive Breast Cancer|ER-Negative Breast Cancer|PR-Negative Breast Cancer|Node-negative Breast Cancer | 2022-01-17 | PHASE2 |
| NCT02326974 | Dana-Farber Cancer Institute|Genentech, Inc. | HER-2 Positive Breast Cancer|Breast Cancer|Stage II Breast Cancer|Stage III Breast Cancer | 2015-01 | PHASE2 |
| NCT02000596 | University of Maryland, Baltimore|Genentech, Inc. | Metastatic Breast Cancer | 2014-01 | PHASE2 |
| NCT02291289 | Hoffmann-La Roche | Colorectal Cancer | 2015-04-17 | PHASE2 |
| NCT04551521 | German Cancer Research Center | Metastatic or Locally Advanced Malignancies | 2021-10-13 | PHASE2 |
| NCT01937117 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Translational Breast Cancer Research Consortium|Genentech, Inc. | Breast Cancer | 2014-01-30 | PHASE2 |
| NCT03878524 | OHSU Knight Cancer Institute|Oregon Health and Science University | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Anatomic Stage IV Breast Cancer AJCC v8|Anemia|Ann Arbor Stage III Hodgkin Lymphoma|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Castration-Resistant Prostate Carcinoma|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Hematopoietic and Lymphoid System Neoplasm|Locally Advanced Pancreatic Adenocarcinoma|Metastatic Breast Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Pancreatic Adenocarcinoma|Myelodysplastic+Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis|Myelodysplastic+Myeloproliferative Neoplasm, Unclassifiable|Primary Myelofibrosis|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Hematologic Malignancy|Recurrent Hodgkin Lymphoma|Recurrent Myelodysplastic Syndrome|Recurrent Myelodysplastic+Myeloproliferative Neoplasm|Recurrent Myeloproliferative Neoplasm|Recurrent Non-Hodgkin Lymphoma|Recurrent Plasma Cell Myeloma|Recurrent Small Lymphocytic Lymphoma|Refractory Acute Lymphoblastic Leukemia|Refractory Acute Myeloid Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Chronic Myelomonocytic Leukemia|Refractory Hematologic Malignancy|Refractory Hodgkin Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Myelodysplastic Syndrome|Refractory Myelodysplastic+Myeloproliferative Neoplasm|Refractory Non-Hodgkin Lymphoma|Refractory Plasma Cell Myeloma|Refractory Primary Myelofibrosis|Refractory Small Lymphocytic Lymphoma|Stage II Pancreatic Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Unresectable Pancreatic Adenocarcinoma | 2020-04-01 | PHASE1 |
| NCT07108127 | Peking Union Medical College Hospital | Rectal Cancer|HER2-positive | 2025-06-20 | PHASE2 |
| NCT05150691 | DualityBio Inc.|BioNTech SE | HER2-positive Advanced Solid Tumor | 2022-01-31 | PHASE1|PHASE2 |
| NCT04188548 | Eli Lilly and Company | Breast Cancer|Advanced Breast Cancer|Metastatic Breast Cancer|Endometrial Cancer | 2019-12-10 | PHASE1 |
| NCT04733118 | MedSIR|Hoffmann-La Roche | Early Breast Cancer | 2021-08-05 | PHASE2 |
| NCT07393425 | Shanghai Jiao Tong University School of Medicine|Jiangsu HengRui Medicine Co., Ltd. | HER2 &addition; Breast Cancer | 2026-02-02 | PHASE2 |
| NCT07402473 | Rutgers, The State University of New Jersey | HER2-positive Early-stage Breast Cancer | 2026-03-26 | PHASE2 |
| NCT07057427 | Henan Cancer Hospital | Breast Cancer | 2025-06-24 | PHASE3 |
| NCT04246502 | Shandong Cancer Hospital and Institute | Metastatic Breast Cancer | 2020-01 | PHASE2 |
| NCT04683445 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Breast Cancer | 2020-12-01 | |
| NCT02266173 | Hoffmann-La Roche | Breast Cancer | 2015-02-05 | |
| NCT02344472 | Prof. Wolfgang Janni|Roche Pharma AG|Novartis Pharmaceuticals|Eisai GmbH|Celgene Corporation | Metastatic Breast Cancer | 2015-09 | PHASE3 |
| NCT01875666 | UNC Lineberger Comprehensive Cancer Center|Genentech, Inc.|Susan G. Komen Breast Cancer Foundation|GlaxoSmithKline | Breast Neoplasms | 2013-08-05 | EARLY_PHASE1 |
| NCT00855894 | Genentech, Inc.|Roche Pharma AG | Non-Small Cell Lung Cancer | 2009-03 | PHASE2 |
| NCT00096993 | Genentech, Inc. | Ovarian Cancer|Peritoneal Cancer|Fallopian Tube Cancer | 2005-01 | PHASE2 |
| NCT07527806 | Peking University Cancer Hospital & Institute | Breast Cancer | 2026-05-01 | PHASE2 |
| NCT03988036 | West German Study Group|Merck Sharp & Dohme LLC|NanoString Technologies, Inc. | Breast Cancer | 2020-08-18 | PHASE2 |
| NCT01048099 | SCRI Development Innovations, LLC|Prometheus Laboratories|Genentech, Inc. | Breast Cancer | 2011-01 | NA |
| NCT02336984 | H. Lee Moffitt Cancer Center and Research Institute | Breast Cancer | 2014-06 | PHASE1|PHASE2 |
| NCT02339532 | UNICANCER | Breast Cancer | 2015-01 | PHASE2 |
| NCT01501487 | Agendia|University of South Florida|University of Miami|Morton Plant Mease Health Care|AdventHealth|Plano Cancer Center|Ohio State University Comprehensive Cancer Center|University of Oklahoma|University of South Alabama | Breast Cancer | 2011-10 | PHASE4 |
| NCT03644186 | ETOP IBCSG Partners Foundation|Pfizer|Hoffmann-La Roche | Breast Cancer|Estrogen Receptor Positive Tumor|HER2-positive Breast Cancer | 2019-04-16 | PHASE2 |
| NCT04395508 | Genentech, Inc. | HER2-positive Breast Cancer | | |
| NCT04158258 | Hoffmann-La Roche|Latin American Cooperative Oncology Group | Breast Cancer | 2020-02-21 | |
| NCT05656079 | Shanghai Pudong Hospital|CSPC Ouyi Pharmaceutical Co., Ltd. | Breast Cancer | 2021-07-01 | NA |
| NCT05188313 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Esophageal Cancer|Esophageal Adenocarcinoma | 2022-03-09 | PHASE3 |
| NCT02586025 | Hoffmann-La Roche | Breast Cancer | 2016-03-14 | PHASE3 |
| NCT04172259 | Sun Yat-sen University|First Affiliated Hospital, Sun Yat-Sen University|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Breast Cancer|Neoadjuvant Chemotherapy | 2019-01-10 | PHASE2 |
| NCT01835236 | Swiss Cancer Institute | Metastatic Breast Cancer | 2013-03-03 | PHASE2 |
| NCT01461057 | Hoffmann-La Roche | Gastric Cancer | 2011-12-06 | PHASE2 |
| NCT01918254 | Hoffmann-La Roche | Breast Cancer | 2013-08-06 | PHASE1 |
| NCT02252887 | Memorial Sloan Kettering Cancer Center|Genentech, Inc.|Hoffmann-La Roche|Hartford HealthCare | Metastatic HER2-Positive Breast Cancer | 2015-01-12 | PHASE2 |
| NCT03329378 | Icahn School of Medicine at Mount Sinai | Locally Advanced Breast Cancer | 2019-01-24 | PHASE2 |
| NCT02593708 | Michelle Melisko | Solid Tumor | 2015-11-03 | PHASE1 |
| NCT05180006 | Gustave Roussy, Cancer Campus, Grand Paris|Hoffmann-La Roche | Breast Cancer | 2022-02-24 | PHASE2 |
| NCT05954143 | Bolt Biotherapeutics, Inc.|Hoffmann-La Roche | Metastatic Breast Cancer|HER2-positive Breast Cancer | 2023-11-30 | PHASE2 |
| NCT00545688 | Hoffmann-La Roche | Breast Cancer | 2006-06-26 | PHASE2 |
| NCT04253561 | SOLTI Breast Cancer Research Group|Roche Pharma AG | Metastatic Breast Cancer | 2020-02-25 | PHASE1 |
| NCT05131893 | National Institute of Oncology, Hungary | Breast Cancer | 2022-03 | |
| NCT04784715 | AstraZeneca|Daiichi Sankyo | Breast Cancer; HER2-positive; Metastatic | 2021-04-26 | PHASE3 |
| NCT04419181 | University of Rochester | HER2-positive Breast Cancer | 2025-08-11 | PHASE2 |
| NCT07470203 | Peking University Cancer Hospital & Institute | HER2-positive Breast Cancer | 2026-03-31 | |
| NCT03304080 | Icahn School of Medicine at Mount Sinai|Herbert Irving Comprehensive Cancer Center|Weill Medical College of Cornell University|NYU Langone Health | Breast Neoplasms|Breast Diseases | 2017-12-20 | PHASE1|PHASE2 |
| NCT05041842 | UNICANCER|Seagen Inc.|ARCAGY+ GINECO GROUP | Metastatic Breast Cancer With a Isolated Brain Progression | 2021-12-17 | PHASE2 |
| NCT07115095 | Nanlin Li | HER2-positive Breast Cancer | 2021-01-01 | NA |
| NCT03238495 | Qamar Khan | HER2-positive Breast Cancer | 2017-08-15 | PHASE2 |
| NCT05283837 | Zydus Lifesciences Limited | Metastatic Breast Cancer | 2022-09-26 | PHASE3 |
| NCT07340398 | Second Affiliated Hospital, School of Medicine, Zhejiang University | HER2-positive Early Breast Cancer | 2025-12-25 | PHASE2 |
| NCT05420467 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Breast Cancer | 2022-07-10 | PHASE4 |